Washington, USA – On February 12, Eieling Technology Limited (hereinafter referred to as ” Eieling Technology “) ushered in an important milestone in the development of its overseas business. The Liverscan®️ series of Portable Liver Elastography Ultrasound Diagnostic System obtained registration approval from the U.S. Food and Drug Administration (FDA). This is the first product of Eieling Technology to obtain U.S. FDA certification.
Liverscan®️’s FDA certification indicates that its safety and effectiveness have been recognized by U.S. regulatory authorities, which means that Eieling Technology’s manufacturing capabilities can meet high standards of quality and lay a solid foundation for the development of Eieling Technology’s overseas business.
The U.S. FDA was established in 1906 and is one of the internationally recognized authoritative organizations. It is authorized by the U.S. Congress, i.e. the federal government, and is the highest law enforcement agency specializing in food and drug management. It is affiliated with the Public Health Service of the U.S. Department of Health and Human Services and is responsible for the management of all food, drugs, cosmetics, and radioactive equipment in the United States. It is also the earliest consumer protection agency in the United States.
The Liverscan®️ series is designed to provide shear wave velocity measurement and tissue stiffness estimation as well as ultrasonic attenuation coefficient measurement of internal body structures, which can be used to assist medical staff in providing comprehensive clinical management for patients with chronic liver disease. This innovative technology can accurately assess the health of the liver, help doctors develop more personalized treatment plans, and improve the quality of life and prognosis of patients. As the flagship product of Eieling Technology, Liverscan®️ has set a new benchmark in the field of chronic liver disease with its superior wireless ultrasound solutions.
The launch of the Liverscan®️ series in the U.S. market will bring new development opportunities to Innovent. The company will take advantage of this opportunity to expand its market share in the field of chronic liver disease further and provide more patients with efficient and convenient diagnosis and treatment services. At the same time, Eieling will continue to increase its R&D investment, continuously innovate and improve its product line, and promote Eieling to achieve greater breakthroughs and achievements in the field of chronic liver disease diagnosis and treatment, and will also contribute more to the development of the field of chronic liver disease diagnosis and treatment!
About Eieling
Eieling Technology was founded in 2018. As a representative of the Department of Biomedical Engineering of the Hong Kong Polytechnic University, it established a basic research and development center in Hong Kong. In 2023, in order to accelerate the expansion of the domestic market, it established a domestic marketing headquarters and engineering research and development and production centers in Shanghai and Shenzhen respectively, focusing on providing portable ultrasound solutions in the field of chronic liver disease.
Since its establishment, Eieling Technology has successively received funding from the Hong Kong Polytechnic University’s Technology Pilot Fund Program. It has successfully joined the Hong Kong Science and Technology Park’s Biomedical Technology Incubation Program (Incu-Bio) and has completed an angel round of financing of HK$10 million in 2023.